Key Takeaways
Odyssey Therapeutics Inc. raised approximately $304 million in a significantly upsized initial public offering, a bullish signal for a biotech sector that has seen investor appetite wax and wane. The company's successful debut points to renewed confidence in clinical-stage companies with a strong scientific platform.
The offering's details were announced in a company press release on Thursday. Odyssey, which will trade on the Nasdaq under the ticker ODTX, is a clinical-stage biopharmaceutical company focused on developing medicines for autoimmune and inflammatory diseases.
The Boston-based company sold 15.5 million shares for $18 each, raising $279 million in its public offering. In a concurrent private placement, an affiliate of TPG Life Sciences Innovations purchased nearly 1.4 million shares at the same price, adding another $25 million. The deal gives Odyssey a market value of about $850.6 million and includes a 30-day option for underwriters to purchase up to 2.3 million additional shares.
This successful offering suggests that investor demand for promising biotech companies remains robust, potentially encouraging other private firms to pursue public listings. The capital raised provides Odyssey with a significant cash runway to advance its portfolio of internally developed medicines, which aim to precisely target the pathology of several inflammatory diseases with unmet needs. The company's first program is already advancing through multiple clinical milestones.
J.P. Morgan, TD Cowen, and Cantor acted as joint book-running managers for the offering.
This article is for informational purposes only and does not constitute investment advice.
